L
LPCN
Lipocine Inc
2.180
+0.020+0.93%Opening13:10 09/30 EDT
OPEN/PREV CLOSE2.070/2.050
TODAY RANGE2.070-2.135
VOL19.76K
MARKET CAP17.07M
52 WEEK RANGE1.810-12.37
AVG VOL (3M)36.22K
% TURNOVER0.21%
TURNOVER--
P/E (TTM)-1.1096
% RANGE3.17%
EPS(TTM)-1.8655
P/E(FORWARD)-1.3398
P/B0.7840
BVPS2.640
DIVIDEND--
P/S6.45
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP16.22M
SHARES OUTSTANDING8.24M
NEXT EARNINGS11/04-11/09
FREE FLOAT7.84M
LOT SIZE1
EX-DATE05/12/2023
News
Press Releases
Financial Reports
Profile
NASDAQ·7h ago
Monday 10/5 Insider Buying Report: LPCN, CSWC
TipRanks·2d ago
Insiders Pile Into Lipocine, Prothena, Pampa, AFC Gamma, ASP
NASDAQ·09/23 16:00
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?
Dow Jones·09/21 16:46
Lipocine Price Target Announced at $4.00/Share by HC Wainwright & Co.
Benzinga·09/21 16:36
HC Wainwright & Co. Reiterates Neutral on Lipocine, Announces $4 Price Target
TipRanks·09/21 16:00
H.C. Wainwright sets $4 price target on Lipocine
TipRanks·09/16 20:58
Lipocine Highlights Strategy at Global Investor Conference
TipRanks·09/14 12:11
Lipocine initiates Phase 3 study of LPCN 1154 for postpartum depression
TipRanks·09/14 10:48
Lipocine Launches Phase 3 BLOOM Study for PPD
TipRanks·09/11 10:29
Lipocine Updates Sales Agreement Fee Structure with A.G.P.
Seeking Alpha·08/04 17:08
Lipocine GAAP EPS of -$0.32, revenue of $190M
Dow Jones·08/04 12:06
*Lipocine 2Q Loss/Shr 32c >LPCN
Dow Jones·08/04 12:06
*Lipocine 2Q Research and Development Expenses $2.0M >LPCN
Same Industry
Name/Symbol
Change%
Price